Testing RXIM002 for severe autoimmune diseases
Part of Immune system & allergy clinical trials.
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with one of these autoimmune diseases: lupus, systemic sclerosis, ITP, inflammatory myopathy, membranous nephropathy, or autoimmune hemolytic anemia.
- Your disease is severe and has come back or not responded to standard treatments.
- A lab test shows your cells are positive for CD19, a protein found on some immune cells.
- You do not have active infections like tuberculosis or hepatitis.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
This trial studies a new treatment called YTS109 for children aged 5 to 18 with certain autoimmune diseases that have not gotten better with standard therapies. The treatment targets and possibly removes a type of immune cell that may be causing the disease.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Hear when a new Relapsed/Refractory B Cell-Mediated Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.